ReviewPediatric transplantation2026
Isolated Kidney Transplant in Primary Hyperoxaluria-1 Enabled by Small Interfering RNA (siRNA) Therapy. Is It Time for Change? Case Report and Review of the Literature.
Review in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary hyperoxaluria type 1 (PH1) is a rare genetic disorder characterized by excessive oxalate production that leads to nephrocalcinosis or nephrolithiasis and progressive kidney failure, associated with systemic oxalosis that is not reversed by dialysis. Pharmacological treatment is limited. Combined or sequential liver and kidney transplant is standard of care for PH1. Recently approved RNA-interference (RNAi) therapy with lumasiran or nedosiran targeting glycolate oxidase and lactate dehydrogenase A, respectively, reduces hepatic oxalate synthesis. This makes kidney-only (isolated) transplantation (iKT) a potentially successful, novel approach for managing PH1 patients with advanced kidney disease combined with hyperhydration, urine alkalinization, and vitamin B6 (where applicable).
methodsWe analyzed the course of a young PH1 kidney transplant recipient at our institution and performed a literature review of patients with small interfering RNA-enabled iKT. CASE PRESENTATION: A patient with PH1 due to a homozygous, pathogenic variant in AGXT exon 1 (c.121G>A; p.Gly41Arg) received a deceased donor kidney transplant after 6.5 years of hemodialysis and 4.3 years of RNAi therapy with lumasiran. He maintained good kidney allograft function 9 months post-transplant despite the occurrence of an asymptomatic calyceal stone within the graft prior to transition to adult nephrology care. At 14 months, he experienced a T cell-mediated rejection, associated with a rise in serum creatinine and plasma oxalate, and a partially obstructing stone. A review of all 10 accessible cases of RNAi-supported iKT, including our own, revealed several instances of kidney stone formation (20%), stent obstruction (20%), and mild, mostly transient crystal deposition in the graft (37.5%).
conclusionsThis report enriches the limited experience of RNAi-enabled kidney-only transplantation in PH1. RNA interference therapy has the potential to challenge the current standard of dual liver and kidney transplantation in children and young adults with this devastating disease but requires uninterrupted access to the drug with individualized, eGFR and oxalate level adjusted dosing, continued vigilance, and reporting of long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.